Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura

Haematologica
Elizabeth M StaleyX Long Zheng

Abstract

Immune-mediated thrombotic thrombocytopenic purpura is characterized by severe thrombocytopenia and microangiopathic hemolytic anemia. It is primarily caused by immunoglobin G type autoantibodies against ADAMTS13, a plasma metalloprotease that cleaves von Willebrand factor. However, reliable markers predictive of patient outcomes are yet to be identified. Seventy-three unique patients with a confirmed diagnosis of immune-mediated thrombotic thrombocytopenic purpura between April 2006 and December 2017 were enrolled from the Univeristy of Alabama at Birmingham Medical Center. Clinical information, laboratory values, and a panel of special biomarkers were collected and/or determined. The results demonstrated that the biomarkers associated with endothelial injury (e.g., von Willebrand factor antigen and collagen-binding activity), acute inflammation (e.g., human neutrophil peptides 1-3 and histone/deoxyribonucleic acid complexes), and activation of the complement alternative pathway (e.g., factors Bb and iC3b) were all significantly increased in patients with acute immune-mediated thrombotic thrombocytopenic purpura compared to those in the healthy controls. Moreover, failure to normalize platelet counts within 7 days or failure t...Continue Reading

Citations

Feb 12, 2019·Journal of Thrombosis and Haemostasis : JTH·Jenny K McDanielX Long Zheng
Sep 12, 2020·Journal of Thrombosis and Haemostasis : JTH·X Long ZhengFlora Peyvandi
Sep 12, 2020·Journal of Thrombosis and Haemostasis : JTH·X Long ZhengFlora Peyvandi
Sep 12, 2020·Journal of Thrombosis and Haemostasis : JTH·X Long ZhengFlora Peyvandi
Apr 4, 2020·Expert Review of Hematology·Andrés Gómez-De LeónDavid Gómez-Almaguer
Jan 19, 2021·La Revue de médecine interne·R PrevelUNKNOWN Centre National de Référence des Microangiopathies Thrombotiques
Jun 2, 2021·Journal of Thrombosis and Haemostasis : JTH·X Long Zheng
Oct 14, 2021·Annals of Hematology·Julio Del Río-GarmaUNKNOWN “Registro Español de la Púrpura Trombocitopénica Trombótica (REPTT)”, and the “Grupo Español de Aféresis (GEA)”

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assay
ELISA

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.